-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED says China regulator grants conditional approval for ORPATHYS in MET-amplified gastric cancer

PUBT·07/02/2026 08:30:25
Listen to the news
HUTCHMED says China regulator grants conditional approval for ORPATHYS in MET-amplified gastric cancer
  • China’s NMPA granted conditional approval for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction cancer.
  • Use covers patients who failed at least two prior systemic treatments, expanding ORPATHYS to a third approved indication in China.
  • Approval was backed by a China Phase II study showing a 32.3% objective response rate, with median duration of response 9.7 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020430PRIMZONEFULLFEED9756041) on July 02, 2026, and is solely responsible for the information contained therein.